Topic:

Emerging Markets

Latest Headlines

Latest Headlines

Wockhardt faces 2nd import alert

Indian generic drugmaker Wockhardt said that a U.K. regulator has issued an import alert for one of its plants in its home country 6 weeks after the FDA banned products from the facility from being shipped to the U.S. 

Fresenius gets 2nd warning letter in 18 months

Fresenius Kabi, the generic drug unit for the German healthcare company, has received its second FDA warning letter n 18 months, this time for a plant in India. And it has had two recent recalls because of glass particles found in vials of injectable drugs.

GlaxoSmithKline faces new allegations over China Botox sales

GlaxoSmithKline is denying allegations that its employees paid Chinese doctors bribes to prescribe drugs, Botox in particular. Even if the company runs afoul of Chinese authorities over the matter, one analyst said any financial fallout would be too small to matter for its bottom line.

Lawsuits mount as India pushes trial reforms

For years, India's poor have been recruited into clinical trials with the promise of life-saving treatment, often without proper consent or education on side effects. Now, as the country works to tighten its regulations, more and more families are suing for retribution.

China taking closer look at drug prices, cost structure

Chinese regulators say they will size up the cost structures and pricing of 60 drugmakers, both domestic and foreign, as it figures out what it should be paying for drugs.

India's move to modernize its medical device regulations appears close

India's push to modernize its medical device regulations for the first time in six years appears close to fruition.

Under new scrutiny, foreign firms 'have to be careful' in China, experts say

In the wake of some well-publicized drug-safety scandals, the Chinese government cracked down on domestic companies. That's changed. Just this week, China has unveiled investigations of four foreign multinationals.

CFR Pharma presses emerging market ambitions with $1.3B Adcock bid

Chilean drugmaker CFR Pharmaceuticals has big plans. After snapping up a Colombian drugmaker late last year and raising $125 million in a bond issue, the company has made a $1.3 billion cash-and-share offer for South Africa's Adcock Ingram.

Turkey's Sanovel joins the emerging-markets deal buffet

The emerging-markets deals just keep popping up. Now, it's a Turkish drugmaker on the block, in a buyout that could be worth $1 billion.

Chinese police corral GlaxoSmithKline employees in bribery probe

Chinese police rounded up GlaxoSmithKline employees in three cities as part of an investigation into "economic crimes," law enforcement there said in a statement. According to as-yet-unconfirmed reports from Chinese media, the detained workers include at least one foreign executive.